Frank L. Jaksch Jr.
CIK: 0001437237
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
Niagen Bioscience, Inc.
Discretionary Trading P&L
Holdings
Transaction History (4 total)
- Jun 24, 2026NAGE
Niagen Bioscience, Inc.
Award(A)DirectStock Option (right to buy)
31.7K shares- - Jun 24, 2025NAGE
Niagen Bioscience, Inc.
Award(A)DirectStock Option (right to buy)
20K shares- - Dec 13, 2024CDXC
ChromaDex Corp.
Exercise(M)Direct50K shares at avg. $3.66$183K - Dec 13, 2024CDXC
ChromaDex Corp.
Sale(S)Direct37.2K shares at avg. $6.19$230K
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Jun 24, 2026 | NAGE Niagen Bioscience, Inc. | Award(A) Stock Option (right to buy) | 31,746 | - | - | Direct |
| Jun 24, 2025 | NAGE Niagen Bioscience, Inc. | Award(A) Stock Option (right to buy) | 20,000 | - | - | Direct |
| Dec 13, 2024 |  CDXC ChromaDex Corp. | Exercise(M) | 50,001 | $3.66 | $183,004 | Direct |
| Dec 13, 2024 | CDXC ChromaDex Corp. | Sale(S) | 37,161 | $6.19 | $229,956 | Direct |
1-4 of 4 transactions
About Jaksch Frank L Jr
Jaksch Frank L Jr (SEC CIK 0001437237) files insider reports with the SEC as Director of Niagen Bioscience, Inc. (NAGE).
Signal8 holds 3 ownership filings by Jaksch Frank L Jr, all Form 4s, filed between Dec 13, 2024 and Jun 26, 2026. Those filings report 4 transactions, from Dec 13, 2024 to Jun 24, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Jaksch Frank L Jr's filings is in LOS ANGELES, CA.
Recent filings by Jaksch Frank L Jr
Other insiders filing for Niagen Bioscience, Inc. (NAGE)
- Lopez Carlos Luis, SVP, General Counsel
- Pamir Ozan, Chief Financial Officer
- Fried Robert N, Chief Executive Officer
- YU Wing Tak Wendy, Director
- Ng Wang Yu Gary, Director
- Cohen Ann, Director